The primary aim of this study was to evaluate the effects of clinical ( 1 mg/day ) and supratherapeutic ( 2 mg/day and 6 mg/day ) multiple oral doses of rasagiline on the baseline - and placebo-adjusted QTc interval ( delta delta QTc ( ddQTc ) ) .